With me today is our CEO, Keyvan Mohajer, and our CFO, Nitesh Sharan. Actual results could differ materially from those ...
AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback